Skip to main content
Premium Trial:

Request an Annual Quote

Chlamydia and Gonorrhea MDx Test from Abbott Cleared by FDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced it has received 510(k) clearance from the US Food and Drug Administration for its molecular diagnostic test and instrument for detecting gonorrhea and chlamydia, including a new strain of chlamydia recently discovered in Sweden.

The clearance covers the Abbott RealTime Chlamydia trachomatis/Neisseria gonorrhoeae, or CT/NG, assay and the Abbott m2000 system. The two must be used together as a system for detecting CT/NG from multiple specimen types, including urine, urethral, vaginal, and endocervical swabs, Abbott said in a statement.

The FDA also cleared Abbott's multi-Collect Specimen Collection unit for the collection and room-temperature transportation of multiple samples, including urine and endocervical, vaginal, and male urethral swab specimens, in one collection device.

The chlamydia test was introduced in the European Union in 2008 to address a new variant strain of the bacteria first identified in Sweden. No reports of the new strain have been reported in the US, but chlamydia remains the most frequently reported sexually transmitted disease in the US, according to the Centers for Disease Control and Prevention, with more than 1.2 million infections reported in 2008, a nine percent increase from the year before.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more